Cyberonics, Inc.  

(Public, NASDAQ:CYBX)   Watch this stock  
Find more results for CYBX
Jul 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 49.65 - 73.52
Open     -
Vol / Avg. 0.00/306,090.00
Mkt cap 1.61B
P/E 30.15
Div/yield     -
EPS 2.00
Shares 26.67M
Beta 0.69
Inst. own 100%
Aug 18, 2014
Q1 2015 Cyberonics Earnings Release (Estimated) Add to calendar
Jun 11, 2014
Cyberonics at William Blair & Company LLC Growth Stock Conference
Jun 4, 2014
Q4 2014 Cyberonics Earnings Release
Jun 4, 2014
Q4 2014 Cyberonics Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '14) 2014
Net profit margin 24.62% 19.46%
Operating margin 31.29% 28.37%
EBITD margin - 33.00%
Return on average assets 26.24% 19.67%
Return on average equity 29.60% 22.47%
Employees 639 -
CDP Score - -


The Cyberonics Building 100 CYBERONICS BLVD
United States - Map
+1-281-2287200 (Phone)
+1-281-2189332 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cyberonics, Inc. (Cyberonics) is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, lead, a programming wand and software and a tunneling tool.

Officers and directors

Daniel J. Moore President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Gregory H. Browne Chief Financial Officer, Senior Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
Rohan J. Hoare Ph.D. Chief Operating Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
David S. Wise Senior Vice President, Chief Administrative Officer, Secretary
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Milton Mayo Morris Ph.D. Senior Vice President - Research & Development
Age: 43
Bio & Compensation  - Reuters
Randal L. Simpson Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Darren W. Alch Vice President, General Counsel, Assistant Secretary
Age: 47
Bio & Compensation  - Reuters
Mark S. Verratti Vice President - Global Sales
Age: 45
Bio & Compensation  - Reuters
Bruce H. KenKnight PhD Vice President - Emerging Therapy
Age: 52
Bio & Compensation  - Reuters
Bryan D. Olin Ph.D. Vice President - Clinical , Quality & Regulatory
Age: 46
Bio & Compensation  - Reuters